Related references
Note: Only part of the references are listed.Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment
Maurien D. Rombouts et al.
ANTICANCER RESEARCH (2020)
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
Carsten Riether et al.
NATURE MEDICINE (2020)
Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus
Chris Wincup et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies
Tae-Eun Park et al.
NATURE COMMUNICATIONS (2019)
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
Martine Bagot et al.
LANCET ONCOLOGY (2019)
Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem
Cecilia Larocca et al.
CLINICAL CANCER RESEARCH (2019)
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim et al.
LANCET ONCOLOGY (2018)
CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia
Carsten Riether et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince et al.
LANCET (2017)
Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
Lisa Argnani et al.
CANCER TREATMENT REVIEWS (2017)
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Philippe Aftimos et al.
CLINICAL CANCER RESEARCH (2017)
Circulating and skin-derived Sezary cells: clonal but with phenotypic plasticity
Marie Roelens et al.
BLOOD (2017)
Cutaneous T-cell lymphoma: 2016 Update on diagnosis, risk-stratification, and management
Ryan A. Wilcox
AMERICAN JOURNAL OF HEMATOLOGY (2016)
CD70: An emerging target in cancer immunotherapy
J. Jacobs et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
Julie Jacobs et al.
ONCOTARGET (2015)
Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy
Catherine G. Chung et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
Karen Silence et al.
MABS (2014)
Alemtuzumab Therapy for Leukemic Cutaneous T-Cell Lymphoma: Diffuse Erythema as a Positive Predictor of Complete Remission
Rei Watanabe et al.
JAMA DERMATOLOGY (2014)
The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma
P. Bertrand et al.
GENES CHROMOSOMES & CANCER (2013)
Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas
Naifu Liu et al.
ONCOTARGETS AND THERAPY (2013)
An electronic chemotherapy administration safety checklist: The safe transition from paper to computer
MiKaela M. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients
Rachael A. Clark et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors
James J. Campbell et al.
BLOOD (2010)
Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome
Remco van Doorn et al.
BLOOD (2009)
Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils
Mami Shibata-Koyama et al.
EXPERIMENTAL HEMATOLOGY (2009)
New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma
Bruce D. Cheson
RADIOLOGIC CLINICS OF NORTH AMERICA (2008)
Share Paper
